Figure 3.

Efficacy of the serum leucine-rich alpha-2 glycoprotein (LRG) level as a biomarker for ulcerative colitis, assessed using the partial Mayo score (PMS), (a) and for Crohn's disease assessed using the Harvey-Bradshaw index (HBI) (b). Receiver operating characteristic (ROC) curves for the serum LRG and C-reactive protein (CRP) levels, as evaluated according to the MS in ulcerative colitis (c) and the HBI in Crohn's disease (d). Values of the area under the ROC curve (AUC) are shown. Clinical remission was defined as MS ≤ 2 in UC and HBI < 5 in CD.